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Background: Graft versus host disease (GvHD) is one of the
most serious complications of hematopoietic cell transplan-
tation (HCT), but its assessment has repeatedly been shown
to vary between healthcare professionals (HCPs). The eGvHD
App was recently developed to support GvHD assessment.
This study aimed to evaluate (1) practice patterns in GvHD
assessment, (2) the added value of using the App compared
to usual methods (UM) on the accuracy, reliability and time
needed to assess GvHD and (3) user experience.
Methods: A multi-center experimental design, with a two-
stage convenience sampling approach, was used to select
Belgian HCT centers (agreeing to organize a GvHD work-
shop) and HCPs (performing at least one GvHD assessment
per year). Using a 1:1 randomization stratiﬁed by profes-
sional background, HCPs were assigned to use either the App
or their usual care GVHD assessment aids (UM) to assess the
diagnosis and severity score of 10 clinical vignettes vali-
dated by a consensus of GvHD experts (gold standard), who
applied the MAGIC and NIH 2014 guidelines for acute (4 vi-
gnettes) and chronic (6 vignettes) GvHD respectively. Answers
of HCPs were scored as “correct” or “incorrect” based on the
gold standard. Professional background and practice pat-
terns were assessed by structured questionnaires and usability
by validated surveys: the technology acceptance model and
Post-Study System Usability Questionnaire. Differences in ac-
curacy and time between the App and UM groups were
compared using a logistic mixed-effect model. A sub-analysis
was done to identify a potential confounding effect for the
type of GvHD, professional background or center effect. Inter-
observer agreement was evaluated by the Brennan-Prediger’s
kappa score.
Results: Seven out of all 11 Belgian HCT centers partici-
pated, corresponding to >80% of the national allogeneic HCT
activity. Seventy-seven HCPs (including 58 (75%) physi-
cians) completed the evaluation. Practice patterns revealed
variety in the GvHD guidelines used in daily practice and low
conﬁdence in GvHD assessment. The App group evaluated sig-
niﬁcantly more vignettes correctly compared to the UM group
for diagnosis (median 65% vs 100% correct; Odds Ratio (OR)
6.14 (95% CI 2.83-13.34)) and scoring (median 45% vs 90%
correct; OR 6.29 (95% CI 4.32-9.15)) (P < .001), with no con-
founding effect identiﬁed. Inter-observer agreement was
higher in the App group, as shown by a signiﬁcantly higher
Kappa score: .46 (95% CI: .23-0.68) for the App group com-
pared to .12 (95% CI: .03-0.21) for the UM group (P = .003).
Despite a median increase of 2.4 minutes per vignette scored
(95% CI: 2.04-2.69) in the App group (P < .001), usability feed-
back was positive.
Conclusion: Using the eGvHD app shows superior accuracy
and reliability for GvHD assessment compared to usual care.
The eGvHD app has therefore the potential to improve the
quality of GvHD data in clinical research and practice.
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Regulatory T cells expressing CD4, CD25, and the transcrip-
tion factor FoxP3 (Treg) play a critical role in suppressing
immune reactions andmaintaining tolerance. Murine studies
have demonstrated that Treg suppress graft-versus-host
disease (GVHD)without limiting the graft-versus-tumor effect.
However, challenges in Treg isolation and ex vivoexpansion
have hampered clinical utilization of these cells. Recently, in
vivo activation through the death receptor 3 (DR3) pathway
Figure 2. Paneth cell count <10 is associated with mortality.
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